학술논문
Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years
Document Type
Article
Author
Source
In Journal of Clinical Lipidology July-August 2017 11(4):986-997
Subject
Language
ISSN
1933-2874